Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...
Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback